Status:
COMPLETED
Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)
Lead Sponsor:
Organon and Co
Conditions:
Pain
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This study will establish the bioequivalence of the 20%, milled, roller compaction final market image (FMI) etoricoxib tablets and 30% unmilled, roller compaction (UMC) etoricoxib tablets.
Eligibility Criteria
Inclusion
- Subject is in good health
- Subject agrees to follow the study guidelines
Exclusion
- Subject is a smoker
- Subject has a history of adverse reactions caused by NSAIDs or allergies/intolerance to NSAIDs
- Subject is in a situation or has a condition/disease which may interfere with optimal participation in the study
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2002
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00945035
Start Date
November 1 2002
End Date
December 1 2002
Last Update
February 9 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.